A share price of UroGen Pharma Ltd [URGN] is currently trading at $20.18, down -3.21%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The URGN shares have gain 11.25% over the last week, with a monthly amount glided 5.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $36. Previously, H.C. Wainwright upgraded its rating to Buy on June 16, 2025, and kept the price target unchanged to $50. On May 22, 2025, downgrade downgraded it’s rating to Neutral. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $23 on April 16, 2025. Guggenheim started tracking with a Buy rating for this stock on August 22, 2024, and assigned it a price target of $40. In a note dated February 08, 2023, Jefferies downgraded an Hold rating on this stock and revised its target price from $35 to $10.
UroGen Pharma Ltd experienced fluctuations in its stock price throughout the past year between $3.42 and $21.71. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $20.18 at the most recent close of the market. An investor can expect a potential return of 16.45% based on the average URGN price forecast.
Analyzing the URGN fundamentals
Trailing Twelve Months sales for UroGen Pharma Ltd [NASDAQ:URGN] were 94.24M which represents 10.83% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.6%, and Net Profit Margin reading is -1.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.74, Equity is 5.03 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.79 points at the first support level, and at 19.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.77, and for the 2nd resistance point, it is at 21.37.
Ratios To Look Out For
To put it in perspective, the Current Ratio for UroGen Pharma Ltd [NASDAQ:URGN] is 4.14. Further, the Quick Ratio stands at 3.99, while the Cash Ratio is 1.95. Considering the valuation of this stock, the price to sales ratio is 9.91.
Transactions by insiders
Recent insider trading involved Degnan Chris, Chief Financial Officer, that happened on Oct 08 ’25 when 2203.0 shares were sold. Chief Medical Officer, Schoenberg Mark completed a deal on Sep 08 ’25 to sell 871.0 shares. Meanwhile, General Counsel Smith Jason Drew sold 1520.0 shares on Sep 08 ’25.
